{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00883870",
      "OrgStudyIdInfo": {
        "OrgStudyId": "SRPL/CLI/07-08/001"
      },
      "Organization": {
        "OrgFullName": "Stempeutics Research Pvt Ltd",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Mesenchymal Stem Cells in Critical Limb Ischemia",
      "OfficialTitle": "A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intramuscular ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Critical Limb Ischemia (Cli)"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2013",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "April 2009"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "February 2010",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "August 2012",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "April 17, 2009",
      "StudyFirstSubmitQCDate": "April 17, 2009",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 20, 2009",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 4, 2013",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 5, 2013",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Stempeutics Research Pvt Ltd",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "This clinical trial aims to study the safety and efficacy of adult mesenchymal stem cells in critical limb ischemia."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Critical Limb Ischemia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "mesenchymal stem cells",
          "critical limb ischemia"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "mesenchymal stem cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intramuscular injection",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intramuscular injection",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Plasmalyte A"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "mesenchymal stem cells",
            "InterventionDescription": "Intramuscular injection",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "mesenchymal stem cells"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Plasmalyte A",
            "InterventionDescription": "Intramuscular injection",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "AE and symptomatic relief",
            "PrimaryOutcomeTimeFrame": "6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Increase in transcutaneous partial oxygen pressure (TcPO2) and Ankle brachial pressure index (ABPI) - measured by Doppler",
            "SecondaryOutcomeTimeFrame": "6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMales or females with non-child bearing potential in the age group of 18-60 yrs of Indian origin.\nEstablished CLI, clinically and hemodynamically confirmed as per Rutherford- II-4, III-5, or III-6; Patients having Infra-inguinal arterial occlusive disease with rest pain or ischemic ulcer/necrosis, who are not eligible for or have failed traditional revascularization treatment (No option patients)\nAnkle Brachial Pressure Index (ABPI) ≤ 0.6 or ankle pressure ≤ 70 mm Hg or TcPO2 ≤ 60 mmHg in the foot\nPatients if having associated Type II Diabetes, should be on medication and well controlled (HbA1c ≤ 8%) without complications\nPatients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits\nNormal liver and renal function\nOn regular medication for hypertension if any\n\nExclusion Criteria:\n\nPatients with CLI suitable for surgical or percutaneous revascularization as determined by the surgeon performing vascular procedure and patients with any acute/chronic inflammatory condition\nCLI patient requiring amputation proximal to trans-metatarsal level\nPatients with gait disturbance for reasons other than CLI.\nType I diabetes\nPatients having respiratory complications/left ventricular ejection fraction < 25%f) Stroke or myocardial infarction within last 3 months\nPatients who are contraindicated for MRA\nHave clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy\nDocumented terminal illness or cancer or any concomitant disease process with a life expectancy of less than 1 year\nPatients already enrolled in another investigational drug trial or completed within 3 months.\nHistory of severe alcohol or drug abuse within 3 months of screening.\nHb% < 10 gm%, Serum Creatinine ≥ 2mg%, Serum Total Bilirubin ≥2mg%, HbA1c > 8%\nWomen with child bearing potential, pregnant and lactating women.\nPatients tested positive for HIV 1, HCV, HBV,",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Suresh K R",
            "OverallOfficialAffiliation": "Bhagawan Mahaveer Jain Heart Centre, Bangalore",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Sanjay Desai",
            "OverallOfficialAffiliation": "M.S.Ramaiah Memorial Hospital, Bangalore",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Rajiv Parakh",
            "OverallOfficialAffiliation": "Sri Ganga Ram Hospital, New Delhi",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Sudhindran S",
            "OverallOfficialAffiliation": "Amrita Institute of Medical Sciences, Kochi",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "M.S.Ramaiah Memorial Hospital",
            "LocationCity": "Bangalore",
            "LocationState": "Karnataka",
            "LocationZip": "560054",
            "LocationCountry": "India"
          },
          {
            "LocationFacility": "Bhagawan Mahaveer Jain Heart Centre",
            "LocationCity": "Bangalore",
            "LocationState": "Karnataka",
            "LocationZip": "5660052",
            "LocationCountry": "India"
          },
          {
            "LocationFacility": "Amrita Institute of Medical Sciences",
            "LocationCity": "Kochi",
            "LocationState": "Kerala",
            "LocationZip": "682026",
            "LocationCountry": "India"
          },
          {
            "LocationFacility": "Sri Ganga Ram Hospital",
            "LocationCity": "New Delhi",
            "LocationZip": "110060",
            "LocationCountry": "India"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "23758736",
            "ReferenceType": "derived",
            "ReferenceCitation": "Gupta PK, Chullikana A, Parakh R, Desai S, Das A, Gottipamula S, Krishnamurthy S, Anthony N, Pherwani A, Majumdar AS. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med. 2013 Jun 10;11:143. doi: 10.1186/1479-5876-11-143."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007511",
            "ConditionMeshTerm": "Ischemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafAsFound": "Ischemia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "C000012499",
            "InterventionMeshTerm": "Plasma-lyte 148"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000009883",
            "InterventionAncestorTerm": "Ophthalmic Solutions"
          },
          {
            "InterventionAncestorId": "D000019999",
            "InterventionAncestorTerm": "Pharmaceutical Solutions"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M85407",
            "InterventionBrowseLeafName": "Plasma-lyte 148",
            "InterventionBrowseLeafAsFound": "Fluorescein",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M11966",
            "InterventionBrowseLeafName": "Ophthalmic Solutions",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}